Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Research article

Association between cyclooxygenase-2 (COX-2) 8473 T > C polymorphism and cancer risk: a meta-analysis and trial sequential analysis

Authors: Qiuping Li, Chao Ma, Zhihui Zhang, Suhua Chen, Weiguo Zhi, Lei Zhang, Guoyao Zhang, Lei Shi, Fei Cao, Tianjiang Ma

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

Numerous studies have investigated the relationship between COX-2 8473 T > C polymorphism and cancer susceptibility, however, the results remain controversial. Therefore, we carried out the present meta-analysis to obtain a more accurate assessment of this potential association.

Methods

In this meta-analysis, 79 case-control studies were included with a total of 38,634 cases and 55,206 controls. We searched all relevant articles published in PubMed, EMBASE, OVID, Web of Science, CNKI and Wanfang Data, till September 29, 2017. The pooled odds ratios (ORs) with 95% confidence intervals (CIs) were used to evaluate the strength of the association. We performed subgroup analysis according to ethnicity, source of controls, genotyping method and cancer type. Moreover, Trial sequential analysis (TSA) was implemented to decrease the risk of type I error and estimate whether the current evidence of the results was sufficient and conclusive.

Results

Overall, our results indicated that 8473 T > C polymorphism was not associated with cancer susceptibility. However, stratified analysis showed that the polymorphism was associated with a statistically significant decreased risk for nasopharyngeal cancer and bladder cancer, but an increased risk for esophageal cancer and skin cancer. Interestingly, TSA demonstrated that the evidence of the result was sufficient in this study.

Conclusion

No significant association between COX-2 8473 T > C polymorphism and cancer risk was detected.
Appendix
Available only for authorised users
Literature
1.
2.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.CrossRefPubMed
3.
Pharoah PD, Dunning AM, Ponder BA, Easton DF. Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer. 2004;4(11):850–60.CrossRefPubMed
4.
Schetter AJ, Heegaard NH, Harris CC. Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis. 2010;31(1):37–49.CrossRefPubMed
5.
6.
O'Callaghan DS, O'Donnell D, O'Connell F, O'Byrne KJ. The role of inflammation in the pathogenesis of non-small cell lung cancer. J Thoracic Oncol. 2010;5(12):2024–36.CrossRef
7.
Hla T, Bishop-Bailey D, Liu CH, Schaefers HJ, Trifan OC. Cyclooxygenase-1 and -2 isoenzymes. Int J Biochem Cell Biol. 1999;31(5):551–7.CrossRefPubMed
8.
Trifan OC, Hla T. Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis. J Cell Mol Med. 2003;7(3):207–22.CrossRefPubMed
9.
Gately S. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev. 2000;19(1–2):19–27.CrossRefPubMed
10.
van Rees BP, Ristimaki A. Cyclooxygenase-2 in carcinogenesis of the gastrointestinal tract. Scand J Gastroenterol. 2001;36(9):897–903.CrossRefPubMed
11.
Gasparini G, Longo R, Sarmiento R, Morabito A. Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? Lancet Oncol. 2003;4(10):605–15.CrossRefPubMed
12.
Cok SJ, Morrison AR. The 3′-untranslated region of murine cyclooxygenase-2 contains multiple regulatory elements that alter message stability and translational efficiency. J Biol Chem. 2001;276(25):23179–85.CrossRefPubMed
13.
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.CrossRefPubMed
14.
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.CrossRefPubMed
15.
16.
Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719–48.PubMed
17.
Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–101.CrossRefPubMed
18.
19.
Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. J Clin Epidemiol. 2008;61(8):763–9.CrossRefPubMed
20.
Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol. 2008;61(1):64–75.CrossRefPubMed
21.
Thorlund K, Imberger G, Wetterslev J, Brok J, Gluud C. Comments on 'Sequential meta-analysis: an efficient decision-making tool' by I van der Tweel and C Bollen. Clin Trials. 2010;7(6):752–3. author reply 754CrossRefPubMed
22.
Cox DG, Pontes C, Guino E, Navarro M, Osorio A, Canzian F, Moreno V. Polymorphisms in prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) and risk of colorectal cancer. Br J Cancer. 2004;91(2):339–43.CrossRefPubMedPubMedCentral
23.
Siezen CL, Bueno-de-Mesquita HB, Peeters PH, Kram NR, van Doeselaar M, van Kranen HJ. Polymorphisms in the genes involved in the arachidonic acid-pathway, fish consumption and the risk of colorectal cancer. Int J Cancer. 2006;119(2):297–303.CrossRefPubMed
24.
Andersen V, Ostergaard M, Christensen J, Overvad K, Tjonneland A, Vogel U. Polymorphisms in the xenobiotic transporter multidrug resistance 1 (MDR1) and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study. BMC Cancer. 2009;9:407.CrossRefPubMedPubMedCentral
25.
Gong Z, Bostick RM, Xie D, Hurley TG, Deng Z, Dixon DA, Zhang J, Hebert JR. Genetic polymorphisms in the cyclooxygenase-1 and cyclooxygenase-2 genes and risk of colorectal adenoma. Int J Color Dis. 2009;24(6):647–54.CrossRef
26.
Thompson CL, Plummer SJ, Merkulova A, Cheng I, Tucker TC, Casey G, Li L. No association between cyclooxygenase-2 and uridine diphosphate glucuronosyltransferase 1A6 genetic polymorphisms and colon cancer risk. World J Gastroenterol. 2009;15(18):2240–4.CrossRefPubMedPubMedCentral
27.
Pereira C, Pimentel-Nunes P, Brandao C, Moreira-Dias L, Medeiros R, Dinis-Ribeiro M. COX-2 polymorphisms and colorectal cancer risk: a strategy for chemoprevention. Eur J Gastroenterol Hepatol. 2010;22(5):607–13.CrossRefPubMed
28.
Andersen V, Holst R, Kopp TI, Tjonneland A, Vogel U. Interactions between diet, lifestyle and IL10, IL1B, and PTGS2/COX-2 gene polymorphisms in relation to risk of colorectal cancer in a prospective Danish case-cohort study. PLoS One. 2013;8(10):e78366.CrossRefPubMedPubMedCentral
29.
Makar KW, Poole EM, Resler AJ, Seufert B, Curtin K, Kleinstein SE, Duggan D, Kulmacz RJ, Hsu L, Whitton J, et al. COX-1 (PTGS1) and COX-2 (PTGS2) polymorphisms, NSAID interactions, and risk of colon and rectal cancers in two independent populations. Cancer Causes Control. 2013;24(12):2059–75.CrossRefPubMedPubMedCentral
30.
Ruan YF, Sun J, Wu F. Relationship between cyclooxygenase-2 polymorphisms and colorectal cancer risk. Int J Dig Dis. 2013;33(4):260–3.
31.
Vogel LK, Saebo M, Hoyer H, Kopp TI, Vogel U, Godiksen S, Frenzel FB, Hamfjord J, Bowitz-Lothe IM, Johnson E, et al. Intestinal PTGS2 mRNA levels, PTGS2 gene polymorphisms, and colorectal carcinogenesis. PLoS One. 2014;9(8):e105254.CrossRefPubMedPubMedCentral
32.
Sakoda LC, Gao YT, Chen BE, Chen J, Rosenberg PS, Rashid A, Deng J, Shen MC, Wang BS, Han TQ, et al. Prostaglandin-endoperoxide synthase 2 (PTGS2) gene polymorphisms and risk of biliary tract cancer and gallstones: a population-based study in shanghai, China. Carcinogenesis. 2006;27(6):1251–6.CrossRefPubMed
33.
Yang H, Gu J, Lin X, Grossman HB, Ye Y, Dinney CP, Wu X. Profiling of genetic variations in inflammation pathway genes in relation to bladder cancer predisposition. Clin Cancer Res. 2008;14(7):2236–44.CrossRefPubMed
34.
Song DK, Chen K, Li LB. Association study of cyclooxygenase 2 polymorphisms and bladder cancer. Chin J Urol. 2008;29(10):704–7.
35.
Gangwar R, Mandhani A, Mittal RD. Functional polymorphisms of cyclooxygenase-2 (COX-2) gene and risk for urinary bladder cancer in North India. Surgery. 2011;149(1):126–34.CrossRefPubMed
36.
Qian Q, Qin J. Relationship between polymorphism of COX-2 and susceptibility of bladder cancer. J Pract Med. 2014;30(7):1076–9.
37.
Gallicchio L, McSorley MA, Newschaffer CJ, Thuita LW, Huang HY, Hoffman SC, Helzlsouer KJ. Nonsteroidal antiinflammatory drugs, cyclooxygenase polymorphisms, and the risk of developing breast carcinoma among women with benign breast disease. Cancer. 2006;106(7):1443–52.CrossRefPubMed
38.
Cox DG, Buring J, Hankinson SE, Hunter DJ. A polymorphism in the 3′ untranslated region of the gene encoding prostaglandin endoperoxide synthase 2 is not associated with an increase in breast cancer risk: a nested case-control study. Breast Cancer Res. 2007;9(1):R3.CrossRefPubMedPubMedCentral
39.
Gao J, Ke Q, Ma HX, Wang Y, Zhou Y, Hu ZB, Zhai XJ, Wang XC, Qing JW, Chen WS, et al. Functional polymorphisms in the cyclooxygenase 2 (COX-2) gene and risk of breast cancer in a Chinese population. J Toxicol Environ Health Part A. 2007;70(11):908–15.CrossRefPubMed
40.
Vogel U, Christensen J, Nexo BA, Wallin H, Friis S, Tjonneland A. Peroxisome proliferator-activated [corrected] receptor-gamma2 [corrected] Pro12Ala, interaction with alcohol intake and NSAID use, in relation to risk of breast cancer in a prospective study of Danes. Carcinogenesis. 2007;28(2):427–34.CrossRefPubMed
41.
Abraham JE, Harrington P, Driver KE, Tyrer J, Easton DF, Dunning AM, Pharoah PD. Common polymorphisms in the prostaglandin pathway genes and their association with breast cancer susceptibility and survival. Clin Cancer Res. 2009;15(6):2181–91.CrossRefPubMed
42.
Piranda DN, Festa-Vasconcellos JS, Amaral LM, Bergmann A, Vianna-Jorge R. Polymorphisms in regulatory regions of cyclooxygenase-2 gene and breast cancer risk in Brazilians: a case-control study. BMC Cancer. 2010;10:613.CrossRefPubMedPubMedCentral
43.
Dossus L, Kaaks R, Canzian F, Albanes D, Berndt SI, Boeing H, Buring J, Chanock SJ, Clavel-Chapelon F, Feigelson HS, et al. PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the breast and prostate Cancer cohort consortium (BPC3). Carcinogenesis. 2010;31(3):455–61.CrossRefPubMed
44.
Brasky TM, Bonner MR, Moysich KB, Ochs-Balcom HM, Marian C, Ambrosone CB, Nie J, Tao MH, Edge SB, Trevisan M, et al. Genetic variants in COX-2, non-steroidal anti-inflammatory drugs, and breast cancer risk: the western New York exposures and breast Cancer (WEB) study. Breast Cancer Res Treat. 2011;126(1):157–65.CrossRefPubMed
45.
Fawzy MS, Aly NM, Shalaby SM, El-Sawy WH, Abdul-Maksoud RS. Cyclooxygenase-2 169C>G and 8473T>C gene polymorphisms and prostaglandin E2 level in breast cancer: a case-control study. Gene. 2013;527(2):601–5.CrossRefPubMed
46.
Gao J, Kang HF, Ma XB, Tang W, Liu D, Zhao Y, Zhang SQ, Guan HT, Lin S, Ren HT, et al. Functional promoter −765 G > C variant in COX-2 gene is associated with the susceptibility of breast cancer in Chinese Han women. Cancer Cell Int. 2014;14:38.CrossRefPubMedPubMedCentral
47.
Lee TS, Jeon YT, Kim JW, Park NH, Kang SB, Lee HP, Song YS. Lack of association of the cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphism with risk of cervical cancer in Korean population. Ann N Y Acad Sci. 2007;1095:134–42.CrossRefPubMed
48.
Pandey S, Mittal RD, Srivastava M, Srivastava K, Mittal B. Cyclooxygenase-2 gene polymorphisms and risk of cervical cancer in a north Indian population. Int J Gynecol Cancer. 2010;20(4):625–30.CrossRefPubMed
49.
Song HL, Li L. Relationship between genetic polymorphism of NF-κB signaling pathway and endometrial carcinoma. Shandong Med J. 2013;53(17):12–4.
50.
Campa D, Hashibe M, Zaridze D, Szeszenia-Dabrowska N, Mates IN, Janout V, Holcatova I, Fabianova E, Gaborieau V, Hung RJ, et al. Association of common polymorphisms in inflammatory genes with risk of developing cancers of the upper aerodigestive tract. Cancer Causes Control. 2007;18(4):449–55.CrossRefPubMed
51.
Ferguson HR, Wild CP, Anderson LA, Murphy SJ, Johnston BT, Murray LJ, Watson RG, McGuigan J, Reynolds JV, Hardie LJ. Cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphisms and risk of reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2008;17(3):727–31.CrossRefPubMed
52.
Upadhyay R, Jain M, Kumar S, Ghoshal UC, Mittal B. Functional polymorphisms of cyclooxygenase-2 (COX-2) gene and risk for esophageal squmaous cell carcinoma. Mutat Res. 2009;663(1–2):52–9.CrossRefPubMed
53.
Lu YJ, Zhang HY, Dai SM. Influence of cyclooxygenase 2 3' untranslated regions genetic polymorphism and interaction with smoking and helicobacter pylori infection on the invasion of esophageal Cancer. China Gen Med J. 2013;16(5):1733–5.
54.
Srivastava K, Srivastava A, Pandey SN, Kumar A, Mittal B. Functional polymorphisms of the cyclooxygenase (PTGS2) gene and risk for gallbladder cancer in a north Indian population. J Gastroenterol. 2009;44(7):774–80.CrossRefPubMed
55.
Jiang GJ, Wang HM, Zhou Y. The correlation study between the nucleotide polymorphism of cyclooxygenase-2 gene and the susceptibility to gastric cancer. Acta Universitatis Medicinalis Nanjing. 2007;27(8):890–4.
56.
Hou L, Grillo P, Zhu ZZ, Lissowska J, Yeager M, Zatonski W, Zhu G, Baccarelli A, Chanock SJ, Fraumeni JF Jr, et al. COX1 and COX2 polymorphisms and gastric cancer risk in a polish population. Anticancer Res. 2007;27(6C):4243–7.PubMed
57.
Li H, Ren C, Fan Z, Jin G, Du J, Liu L, Zhu C, Lu F, Ding Y, Deng B, et al. A genetic variant in 3′-untranslated region of cyclooxygenases-2 gene is associated with risk of gastric cancer in a Chinese population. DNA Cell Biol. 2012;31(7):1252–7.CrossRefPubMed
58.
Gao F, Lu L, Qin JD, Zhang B. Single nucleotide polymorphism in COX-2 gene are associated with risk of non-cardia gastric Cancer. Cancer Res Prev Treat. 2015;42(5):470–3.
59.
Lin RP, Yao CY, Ren DX. Association between genetic polymorphisms of PTGS2 and glioma in a Chinese population. Genet Mol Res. 2015;14(2):3142–8.CrossRefPubMed
60.
Akkiz H, Bayram S, Bekar A, Akgollu E, Ulger Y. Functional polymorphisms of cyclooxygenase-2 gene and risk for hepatocellular carcinoma. Mol Cell Biochem. 2011;347(1–2):201–8.CrossRefPubMed
61.
Shao SS, Fu ZZ, Wang GX. Association of COX-2 8473T>C genetic variant and risk of primary hepatic carcinoma. J Hebei United Univ. 2014;16(2):141–2.
62.
Chang JS, Lo HI, Wong TY, Huang CC, Lee WT, Tsai ST, Chen KC, Yen CJ, Wu YH, Hsueh WT, et al. Investigating the association between oral hygiene and head and neck cancer. Oral Oncol. 2013;49(10):1010–7.CrossRefPubMed
63.
Niu Y, Yuan H, Shen M, Li H, Hu Y, Chen N. Association between cyclooxygenase-2 gene polymorphisms and head and neck squamous cell carcinoma risk. J Craniofac Surg. 2014;25(2):333–7.CrossRefPubMed
64.
Campa D, Zienolddiny S, Maggini V, Skaug V, Haugen A, Canzian F. Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis. 2004;25(2):229–35.CrossRefPubMed
65.
Hu Z, Miao X, Ma H, Wang X, Tan W, Wei Q, Lin D, Shen H. A common polymorphism in the 3'UTR of cyclooxygenase 2/prostaglandin synthase 2 gene and risk of lung cancer in a Chinese population. Lung cancer. 2005;48(1):11–7.CrossRefPubMed
66.
Sorensen M, Autrup H, Tjonneland A, Overvad K, Raaschou-Nielsen O. A genetic polymorphism in prostaglandin synthase 2 (8473, T-->C) and the risk of lung cancer. Cancer Lett. 2005;226(1):49–54.CrossRefPubMed
67.
Campa D, Hung RJ, Mates D, Zaridze D, Szeszenia-Dabrowska N, Rudnai P, Lissowska J, Fabianova E, Bencko V, Foretova L, et al. Lack of association between polymorphisms in inflammatory genes and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2005;14(2):538–9.CrossRefPubMed
68.
Park JM, Choi JE, Chae MH, Lee WK, Cha SI, Son JW, Kim CH, Kam S, Kang YM, Jung TH, et al. Relationship between cyclooxygenase 8473T>C polymorphism and the risk of lung cancer: a case-control study. BMC Cancer. 2006;6:70.CrossRefPubMedPubMedCentral
69.
Vogel U, Christensen J, Wallin H, Friis S, Nexo BA, Raaschou-Nielsen O, Overvad K, Tjonneland A. Polymorphisms in genes involved in the inflammatory response and interaction with NSAID use or smoking in relation to lung cancer risk in a prospective study. Mutat Res. 2008;639(1–2):89–100.CrossRefPubMed
70.
Lim WY, Chen Y, Ali SM, Chuah KL, Eng P, Leong SS, Lim E, Lim TK, Ng AW, Poh WT, et al. Polymorphisms in inflammatory pathway genes, host factors and lung cancer risk in Chinese female never-smokers. Carcinogenesis. 2011;32(4):522–9.CrossRefPubMed
71.
Guo S, Li X, Gao M, Kong H, Li Y, Gu M, Dong X, Niu W. Synergistic association of PTGS2 and CYP2E1 genetic polymorphisms with lung cancer risk in northeastern Chinese. PLoS One. 2012;7(6):e39814.CrossRefPubMedPubMedCentral
72.
Bhat IA, Rasool R, Qasim I, Masoodi KZ, Paul SA, Bhat BA, Ganaie FA, Aziz SA, Shah ZA. COX-2 overexpression and −8473 T/C polymorphism in 3' UTR in non-small cell lung cancer. Tumour Biol. 2014;35(11):11209–18.CrossRefPubMed
73.
Cao Q, Yang Y, Xu R. Research on the relationship between cyclooxygenase-2 polymorphisms and non-small cell lung cancer susceptibility. Chin J Exp Surg. 2015;32(9):2264–6.
74.
Moraes JL, Moraes AB, Aran V, Alves MR, Schluckbier L, Duarte M, Toscano E, Zamboni M, Sternberg C, de Moraes E, et al. Functional analysis of polymorphisms in the COX-2 gene and risk of lung cancer. Mol Clin Oncol. 2017;6(4):494–502.CrossRefPubMedPubMedCentral
75.
Mamoghli T, Douik H, Mehri S, Ghanem A, Ben Chaabane A, Bouassida J, Kablouti G, Harzallah L, Gritli S, Guemira F. The CC-genotype of the cyclooxygenase-2 gene associates with decreased risk of nasopharyngeal carcinoma in a Tunisian population. Pathologie-biologie. 2015;63(1):7–10.CrossRefPubMed
76.
Wang JL, Wang X, Yang D, Shi WJ. Association between 8473T>C polymorphism in the cyclooxygenase-2 gene and the risk of nasopharyngeal carcinoma. Int J Clin Exp Pathol. 2015;8(6):7441–5.PubMedPubMedCentral
77.
Lan XH, Chen N, Fan TH. Study on the risk relationship between cyclooxygenase 2 gene polymorphism and oral cancer. China Modern Doctor. 2014;52(32):4–8.
78.
Lurie G, Terry KL, Wilkens LR, Thompson PJ, McDuffie KE, Carney ME, Palmieri RT, Cramer DW, Goodman MT. Pooled analysis of the association of PTGS2 rs5275 polymorphism and NSAID use with invasive ovarian carcinoma risk. Cancer Causes Control. 2010;21(10):1731–41.CrossRefPubMedPubMedCentral
79.
Ozhan G, Lochan R, Leathart JB, Charnley R, Daly AK. Cyclooxygenase-2 polymorphisms and pancreatic cancer susceptibility. Pancreas. 2011;40(8):1289–94.CrossRefPubMed
80.
Shahedi K, Lindstrom S, Zheng SL, Wiklund F, Adolfsson J, Sun J, Augustsson-Balter K, Chang BL, Adami HO, Liu W, et al. Genetic variation in the COX-2 gene and the association with prostate cancer risk. Int J Cancer. 2006;119(3):668–72.CrossRefPubMed
81.
Cheng I, Liu X, Plummer SJ, Krumroy LM, Casey G, Witte JS. COX2 genetic variation, NSAIDs, and advanced prostate cancer risk. Br J Cancer. 2007;97(4):557–61.CrossRefPubMedPubMedCentral
82.
Danforth KN, Hayes RB, Rodriguez C, Yu K, Sakoda LC, Huang WY, Chen BE, Chen J, Andriole GL, Calle EE, et al. Polymorphic variants in PTGS2 and prostate cancer risk: results from two large nested case-control studies. Carcinogenesis. 2008;29(3):568–72.CrossRefPubMed
83.
Mandal RK, Mittal RD. Polymorphisms in COX-2 gene influence prostate cancer susceptibility in a northern Indian cohort. Arch Med Res. 2011;42(7):620–6.CrossRefPubMed
84.
Lira MG, Mazzola S, Tessari G, Malerba G, Ortombina M, Naldi L, Remuzzi G, Boschiero L, Forni A, Rugiu C, et al. Association of functional gene variants in the regulatory regions of COX-2 gene (PTGS2) with nonmelanoma skin cancer after organ transplantation. Br J Dermatol. 2007;157(1):49–57.CrossRefPubMed
85.
Vogel U, Christensen J, Wallin H, Friis S, Nexo BA, Tjonneland A. Polymorphisms in COX-2, NSAID use and risk of basal cell carcinoma in a prospective study of Danes. Mutat Res. 2007;617(1–2):138–46.CrossRefPubMed
86.
Gomez-Lira M, Tessari G, Mazzola S, Malerba G, Rugiu C, Naldi L, Nacchia F, Valerio F, Anna B, Forni A, et al. Analysis of the 3'UTR of the prostaglandin synthetase-2 (PTGS-2/COX-2) gene in non-melanoma skin cancer after organ transplantation. Exp Dermatol. 2011;20(12):1025–7.CrossRefPubMed
87.
Wang JM, Ko CY, Chen LC, Wang WL, Chang WC. Functional role of NF-IL6beta and its sumoylation and acetylation modifications in promoter activation of cyclooxygenase 2 gene. Nucleic Acids Res. 2006;34(1):217–31.CrossRefPubMedPubMedCentral
88.
Sheng H, Shao J, Dixon DA, Williams CS, Prescott SM, DuBois RN, Beauchamp RD. Transforming growth factor-beta1 enhances ha-ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA. J Biol Chem. 2000;275(9):6628–35.CrossRefPubMed
89.
Kuersten S, Goodwin EB. The power of the 3' UTR: translational control and development. Nat Rev Genet. 2003;4(8):626–37.CrossRefPubMed
90.
Moraitis D, Du B, De Lorenzo MS, Boyle JO, Weksler BB, Cohen EG, Carew JF, Altorki NK, Kopelovich L, Subbaramaiah K, et al. Levels of cyclooxygenase-2 are increased in the oral mucosa of smokers: evidence for the role of epidermal growth factor receptor and its ligands. Cancer Res. 2005;65(2):664–70.PubMed
91.
Liu F, He Y, Peng X, Wang W, Yang X. Association of the 8473T>C cyclooxygenase-2 (COX-2) gene polymorphism with lung cancer risk in Asians. Asian Pac J Cancer Prev. 2010;11(5):1257–62.PubMed
92.
Zhu W, Wei BB, Shan X, Liu P. -765G>C and 8473T>C polymorphisms of COX-2 and cancer risk: a meta-analysis based on 33 case-control studies. Mol Biol Rep. 2010;37(1):277–88.CrossRefPubMed
93.
Pan F, Tian J, Pan Y, Zhang Y. Lack of association of the cyclooxygenase 8473 T>C polymorphism with lung cancer: evidence from 9841 subjects. Asian Pac J Cancer Prev. 2011;12(8):1941–5.PubMed
Metadata
Title
Association between cyclooxygenase-2 (COX-2) 8473 T > C polymorphism and cancer risk: a meta-analysis and trial sequential analysis
Authors
Qiuping Li
Chao Ma
Zhihui Zhang
Suhua Chen
Weiguo Zhi
Lei Zhang
Guoyao Zhang
Lei Shi
Fei Cao
Tianjiang Ma
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-4753-3

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue

Research article

Compared characteristics of current vs. past smokers at the time of diagnosis of a first-time lung or head and neck cancer: a cross-sectional study

Study protocol

CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer

Research article

Vemurafenib in Chinese patients with BRAFV600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study

Debate

Circular RNA: new star, new hope in cancer

Research article

RNA-Seq reveals the existence of a CDKN1C-E2F1-TP53 axis that is altered in human T-cell lymphoblastic lymphomas

Study protocol

The Brainfit study: efficacy of cognitive training and exergaming in pediatric cancer survivors – a randomized controlled trial
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits